Inhaled Insulin Therapy Drug Resubmitted for FDA Approval

MannKind again filed an application with the FDA for approval to market its Afrezza inhalation powder, a fast mealtime insulin treatment intended to improve glycemic control for diabetes patients. The application was based on data from two late-stage trials. Mannkind Press Release Oct 2013